Drug developer Satellos wins FDA clearance to trial forazapadin in FSHD
The FSHD Canada Foundation will provide up to $5 million in non-dilutive financing, with a Phase 2 study expected in Q4 2026.
Intelligence
The parties
Activity
The FSHD Canada Foundation will provide up to $5 million in non-dilutive financing, with a Phase 2 study expected in Q4 2026.
Intelligence
Activity